Opdivo vs Keytruda
Side-by-side comparison of Opdivo and Keytruda — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Opdivo | Keytruda |
|---|
| Generic name | nivolumab | pembrolizumab |
|---|
| Sponsor | Bristol-Myers Squibb | Merck & Co. |
|---|
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] | Monoclonal antibody; PD-1 inhibitor |
|---|
| Molecular target | Programmed cell death protein 1 | PD-1 receptor |
|---|
| Modality | Monoclonal antibody | Monoclonal antibody |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Oncology | Oncology |
|---|
| First approval | 2014 | 2014-09-04 |
|---|
Mechanism of action
| Opdivo | Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells. |
|---|
| Keytruda | Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response. |
|---|
Approved indications
Opdivo
- Advanced melanoma with tumour cell PD-L1 expression below 1%
- Classical Hodgkin lymphoma
- Head and neck cancer
- Malignant tumor of esophagus
- Malignant tumor of stomach
- Metastatic malignant melanoma
- Metastatic renal cell carcinoma
- Microsatellite instability-high colorectal cancer
Keytruda
- Melanoma
- NSCLC (nonsquamous)
- NSCLC (squamous)
- NSCLC (PD-L1+)
- NSCLC (PD-L1+, post-platinum)
- NSCLC (neoadjuvant)
- NSCLC (adjuvant)
- MPM
Common side effects
Opdivo
- Fatigue
- Rash
- Musculoskeletal pain
- Pruritus
- Diarrhea
- Nausea
- Asthenia
- Cough
Keytruda
- Nausea
- Fatigue
- Anaemia
- Diarrhoea
- Constipation
- Decreased appetite
- Hypothyroidism
- Vomiting
Further reading